Levitee Labs is breaking out, up 10% so far. They just gave an update on their addiction and pain service acquisition strategy. The portfolio currently includes five addiction clinics, three specialized pharmacies, and a technology company (BlockMD). An additional LOI has been signed for a controlling interest in a Calgary addiction/compounding clinic. Plus, $LVT will partner with $WELL’s Adracare to further improve its digital/telemedicine offerings. The article is worth a look.
https://ca.finance.yahoo.com/news/levitee-clinics-levitee-pharmacies-insight-120000331.html
What sets $LVT apart from its competitors (other than actual revenue generation) is the diversification of its portfolio. Many of $LVT’s competitors only focus on one sector in the market, limiting the opportunity to scale since they rely on only psychedelics. And the aggressive growth strategy seems to be paying off right now. August revenues were up 10% over July (to $893,873), led by organic and acquired growth. Considering how they’ve continued developing and growing their businesses, I’m expecting October revenues to be around $1M-$1.2M.
Considering the $29M market cap, if they continue to generate revenues of around $1M per month, they should have a 12m price to revenue ratio of approximately 2.4 (not accounting for any further growth and revenue projections). Compared to peers with ratios of 10x+, $LVT is definitely one of the most undervalued psychedelic companies on the market, GLTA!